2-[1-(1-Hydroxymethyl-cyclopentylcarbamoyl)-cyclopentylmethyl]-pentanoic acid tert-butyl ester | 337962-92-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[1-(1-Hydroxymethyl-cyclopentylcarbamoyl)-cyclopentylmethyl]-pentanoic acid tert-butyl ester
• 英文别名: Tert-butyl 2-[[1-[[1-(hydroxymethyl)cyclopentyl]carbamoyl]cyclopentyl]methyl]pentanoate
• CAS: 337962-92-2
• 化学式: C₂₂H₃₉NO₄
• 分子量: 381.556
• InChiKey: MKDXWZKDRMPETN-UHFFFAOYSA-N

物化性质

• 沸点：
  523.7±23.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[1-(1-Hydroxymethyl-cyclopentylcarbamoyl)-cyclopentylmethyl]-pentanoic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以97%的产率得到2-((1-((1-(Hydroxymethyl)cyclopentyl)carbamoyl)cyclopentyl)methyl)pentanoic acid
  参考文献：
  名称：

  Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides

  摘要：

  Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)

  DOI：

  10.1021/jm060133g
• 作为产物：
  描述：

  3-溴丙酸叔丁酯 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， -65.0~100.0 ℃ 、206.84 kPa 条件下， 反应 17.17h， 生成 2-[1-(1-Hydroxymethyl-cyclopentylcarbamoyl)-cyclopentylmethyl]-pentanoic acid tert-butyl ester
  参考文献：
  名称：

  Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides

  摘要：

  Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)

  DOI：

  10.1021/jm060133g

文献信息

• Novel Selective Inhibitors of Neutral Endopeptidase for the Treatment of Female Sexual Arousal Disorder. Synthesis and Activity of Functionalized Glutaramides
  作者：David C. Pryde、Graham N. Maw、Simon Planken、Michelle Y. Platts、Vivienne Sanderson、Martin Corless、Alan Stobie、Christopher G. Barber、Rachel Russell、Laura Foster、Laura Barker、Christopher Wayman、Piet Van Der Graaf、Peter Stacey、Debbie Morren、Christopher Kohl、Kevin Beaumont、Sara Coggon、Michael Tute

  DOI：10.1021/jm060133g

  日期：2006.7.1

  Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)